Sandoz unveils global action plan to improve access to biosimilars

Nicole DeFeudis

Editor

As the spotlight trains on access to biosimilars, Novartis’ generics unit on Thursday released a global action plan to boost biosimilar adoption by 2030. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sandoz unveils global action plan to improve access to biosimilars

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

San­doz un­veils glob­al ac­tion plan to im­prove ac­cess to biosim­i­lars

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sandoz unveils global action plan to improve access to biosimilars